Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a prospective, open-label, single-center, randomized controlled Phase II clinical study aimed at evaluating the efficacy and safety of neoadjuvant imlunestrant combined with abemaciclib guided by the Ki67 index after 2 weeks in patients with ER+/HER2- breast cancer.
Epistemonikos ID: 943ff01c6890754f51a58e5c92c99b0b17ba109f
First added on: Feb 14, 2026